



NEWS FLASH

February 5, 2010

NEW GENERICS

azelastine

(Apotex)

0.05% Ophthalmic Solution

Reference Brand: OPTIVAR

NOW AVAILABLE

MEDICATION SHORTAGES

The following medications are reportedly in short supply and may be temporarily unavailable in pharmacies nationwide:

- ◆ Acyclovir tablets (all strengths)
- ◆ Amnesteem 20mg capsule
- ◆ Armour Thyroid tablets (all strengths)
- ◆ Buprenorphine tablets (all strengths)
- ◆ Clonidine patches (all strengths)
- ◆ Gemfibrozil 600mg tablets
- ◆ Hydromorphone 1mg/mL syringe
- ◆ Hydromorphone 2mg/mL syringe
- ◆ Levothyroid tablets (all strengths)
- ◆ Lexapro 5mg/5mL oral solution
- ◆ Ortho Tri-Cyclen Lo tablets
- ◆ Promethegan 25mg suppository
- ◆ Propofol 10mg/mL vial
- ◆ Valacyclovir 500mg tablets
- ◆ Vivelle-Dot 0.075mg/24hr patches

NEW FDA APPROVALS / NEW INDICATIONS

BRAND NAME	STRENGTH	FDA APPROVED INDICATION	MARKET STATUS
AMPYRA dalfampridine <i>ACORDA</i>	10mg extended-release tabs	An oral treatment to improve walking in patients with all 4 types of multiple sclerosis (relapsing remitting, secondary progressive, progressive relapsing, and primary progressive). AMPYRA can be used alone or with other multiple sclerosis therapies, including immunomodulator drugs.	Expected in March 2010
JUVEDERM XC hyaluronic acid & lidocaine <i>ALLERGAN</i>	Injectable	New formulation of the currently FDA-approved JUVÉDERM® dermal filler, which contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment of moderate to severe facial wrinkles and folds.	Approval
OLEPTRO trazodone <i>LABOPHARM</i>	150mg, 300mg extended-release tabs	Extended-release tablets for the once-daily treatment of major depressive disorder in adults.	Expected in late 2010
VICTOZA liraglutide <i>NOVO NORDISK</i>	0.6mg Injectable	As an adjunct to diet, exercise, and other medications for the treatment of type 2 diabetes in adults. VICTOZA is a glucagon-like peptide-1 (GLP-1) receptor agonist used as a once-daily injection that stimulates insulin production following a meal. The drug was approved with a Risk Evaluation and Mitigation Strategy (REMS) program that includes a Medication Guide and communication plan.	Approval
XIAFLEX collagenase Clostridium histolyticum <i>AUXILIUM PHARMA</i>	Injectable	For the treatment of <i>Dupuytren contracture</i> , a progressive hand disease that affects straightening and proper use of the fingers. XIAFLEX is a biologic drug that works by breaking down excessive collagen buildup in the hand. It is injected directly into the collagen cord of the hand.	Approval

FDA NEWS / ALERTS

TYSABRI (natalizumab) - The FDA is alerting the public that the risk of developing progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection associated with the use of TYSABRI, increases with the number of TYSABRI infusions received. This new safety information, based on reports of 31 confirmed cases of PML received by the FDA as of January 21, 2010, will now be included in the TYSABRI drug label and patient Medication Guide. TYSABRI was approved by the FDA in November 2004 for the treatment of relapsing forms of multiple sclerosis (MS). TYSABRI is also approved for treating moderately to severely active Crohn's disease.

For more information about FDA alerts please visit <http://www.fda.gov>

An archive of previous newsletter issues available at www.procarerx.com